Browse Category

NYSE:AES News 1 October 2025

AES Corp Stock Skyrockets as BlackRock Nears $38B Takeover – What Investors Need to Know /updated: 3:00 PM EDT/

AES Corp Stock Skyrockets as BlackRock Nears $38B Takeover – What Investors Need to Know /updated: 3:00 PM EDT/

Stock Price & Recent Trading AES shares have rallied sharply in late September. As of Oct 1 the stock was around $15.3 – up over 15% on the day reuters.com. This was the largest single-day jump in nearly a year, triggered by takeover rumors. Trading volume spiked; Reuters notes AES was “boosting the S&P 500 utilities sector” as investors flocked in reuters.com. Before this move, AES had been in a year-long slump (down ~30% from last year’s high), but a minor rebound in recent weeks was dramatically accelerated by the BlackRock/GIP news. Over the last few days (Sept 28–Oct 1) the stock gyrated on deal speculation:

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop